@prefix dcterms: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix rdf: .
@prefix nt: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix bl: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
bl:category bl:Disease .
sub:association rdf:object ;
rdf:predicate bl:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "phentermine hydrochloride orally disintegrating tablets are sympathomimetic amine anorectic indicated as a short term adjunct a few weeks in a regimen of weight reduction based on exercise behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 3 kg m 2 2 1 the limited usefulness of agents of this class including phentermine hydrochloride should be measured against possible risk factors inherent in their use 1 phentermine hydrochloride orally disintegrating tablets are indicated as a short term a few weeks adjunct in a regimen of weight reduction based on exercise behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 3 kg m 2 2 below is a chart of body mass index bmi based on various heights and weights bmi is calculated by taking the patient s weight in kilograms kg divided by the patient s height in meters m squared metric conversions are as follows pounds 2 2 kg inches x 254 meters body mass index bmi kg m 2 header weight 5 5 3 5 6 5 9 6 6 3 14 27 25 23 21 19 18 15 29 27 24 22 2 19 16 31 28 26 24 22 2 17 33 3 28 25 23 21 18 35 32 29 27 25 23 19 37 34 31 28 26 24 2 39 36 32 3 27 25 21 41 37 34 31 29 26 22 43 39 36 33 3 28 23 45 41 37 34 31 29 24 47 43 39 36 33 3 25 49 44 4 37 34 31 the limited usefulness of agents of this class including phentermine hydrochloride see clinical pharmacology 12 1 12 2";
bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
bl:provided_by ;
bl:relation schema:TreatmentIndication .
bl:category bl:Drug .
}
sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "Z5156CrHSToPkzrjZE9s6SPVigBAAVoqFvgrjYoyFSrHmO2ERENmLherx51WE6yZ64YovWtmZqAm4M7CSZO84/x3zthXvmZVBpU35sCyYWfwLl5InMB1E+iLvoqRRe9il4SKIVmag++A5LjVR0qVwziDHgZnLvKSWq2Hyx/1Zog=";
npx:hasSignatureTarget this: .
this: dcterms:created "2021-06-27T20:27:35.302+02:00"^^xsd:dateTime;
dcterms:creator orcid:0000-0002-1468-3557;
nt:wasCreatedFromProvenanceTemplate ;
nt:wasCreatedFromPubinfoTemplate ;
nt:wasCreatedFromTemplate .
}